Alere
Financials
Estimates*
EUR | 2015 | 2016 |
---|---|---|
R&D budget | 93.0m | 100m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.4m | Debt | ||
N/A | $100m | Debt | |
$5.3b | Acquisition | ||
Total Funding | - |
Related Content
Recent News about Alere
EditAbbott, formerly known as Alere, specializes in rapid point-of-care (POC) diagnostic solutions. The company operates in the healthcare sector, providing critical diagnostic tools that deliver immediate and actionable results. Abbott's product portfolio includes tests for infectious diseases, cardiometabolic conditions, and toxicology, serving a wide range of clients from individual consumers to healthcare providers and institutions. The company's business model revolves around selling diagnostic devices and tests, generating revenue through product sales and service contracts. Abbott's innovative solutions, such as the NAVICA app and the COVID-19 Ag Card, have received U.S. Food and Drug Administration Emergency Use Authorization (EUA), highlighting their commitment to addressing urgent healthcare needs. The company operates globally, although product availability may vary by region.
Keywords: rapid diagnostics, point-of-care, infectious diseases, cardiometabolic, toxicology, healthcare, NAVICA app, COVID-19 Ag Card, FDA EUA, global healthcare.